Cucurbitacins as inducers of cell death and a rich source of potential anticancer compounds

Current Pharmaceutical Design

Volumn 18, Issue 12, 2012, Pages 1663-1676

  Rios J L ^a   Andujar I ^a   Escandell, J M ^a   Giner, R M ^a   Recio, M C ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Apoptosis; Cancer; Cell death; Cucurbitacins; JAK STAT

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; CISPLATIN; CUCURBITACIN; CUCURBITACIN B; CUCURBITACIN D; CUCURBITACIN E; CUCURBITACIN I; CUCURBITACIN IIA; CUCURBITACIN R; CYCLIN D3; CYTOSTATIC AGENT; DIHYDROCUCURBITACIN B; DOCETAXEL; GEMCITABINE; JANUS KINASE; JANUS KINASE 3; JSI 124; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR FACTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; STAT PROTEIN; STAT3 PROTEIN; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SELECTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LARYNX CANCER; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CUCURBITACINS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84860147482     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799958549     Document Type: Article

References (79)

1. Peter ME. Programmed cell death: Apoptosis meets necrosis. Nature 2011; 471: 310-312.
2. Kroemer G, Galluzzi L, Vandenabeele P, et al. Nomenclature Committee on Cell Death 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16: 3-11.
3. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-445.
4. Miyashita T, Reed J C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
5. Ravizza R, Gariboldi MB, Passarelli L, Monti E. Role of the p53/p21 system in the response of human colon carcinoma cells to doxorubicin. BMC Cancer 2004; 4: 92.
6. (WAF1/CIP) gene. Exp Cell Res 1999; 246: 280-289
7. Levy DE, Darnell JE Jr. STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662.
8. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005; 28: 187-196.
9. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 2007; 13: 5665-5669.
10. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357-358.
11. Aggarwal BB, Sethi G, Ahn KS, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006; 1091: 151-169.
12. Darnell JE Jr. STATs and gene regulation. Science 1997; 277: 1630-1635.
13. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995; 64: 621-651.
14. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11-9.
15. Deng J, Grande F, Neamati N. Small molecule inhibitors of STAT3 signaling pathway. Curr Cancer Drug Targets 2007; 7: 91-107.
16. Jing N, Tweardy DJ. Targeting STAT3 in cancer therapy. Anticancer Drugs 2005; 16: 601-607.
17. Rivat C, Rodrigues S, Bruyneel E, et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) - and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 2005; 65: 195-202. Erratum in: Cancer Res 2005; 65: 2505.
18. Shynu M, Gupta PK, Saini M. Antineoplastic potential of medicinal plants. Recent Pat Biotechnol 2011; 5: 85-94.
19. Kado K, Forsyth A, Patel PR, Schwartz JA. Dietary supplements and natural products in breast cancer trials. Front Biosci (Elite Ed) 2012; 4: 546-567.
20. Russo P, Nastrucci C, Cesario A. From the sea to anticancer therapy. Curr Med Chem 2011; 18: 3551-3562.
21. Kinghorn AD, Pan L, Fletcher JN, Chai H. The relevance of higher plants in lead compound discovery programs. J Nat Prod 2011; 74: 1539-1555.
22. Pan L, Chai HB, Kinghorn AD. Discovery of new anticancer agents from higher plants. Front Biosci (Schol Ed) 2012; 4: 142-156.
23. Fulda S. Modulation of apoptosis by natural products for cancer therapy. Planta Med 2010; 76: 1075-1079.
24. Ovesna Z, Vachalkova A, Horvathova K, Tothova D. Pentacyclic triterpenoic acids: new chemoprotective compounds. Neoplasma 2004; 51: 327-333
25. Cipak L, Grausova L, Miodokova E, Novotny L, Rauko P. Dual activity of triterpenoids: apoptotic versus antidifferentiation effects. Arch Toxicol 2006; 80: 429-435.
26. Laszczyk MN. Pentacyclic triterpenes of the lupine, loleanane and ursane group as tools in cancer therapy. Planta Med 2009; 75: 1549-1560
27. Ríos JL, Recio MC, Escandell JM, Andújar I. Inhibition of transcription factors by plant-derived compounds and their implications in inflammation and cancer. Curr Pharm Des 2009; 15: 1212-1237.
28. Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: ancient compound shedding new light on cancer treatment. Sci World J 2010; 10: 413-418.
29. Miró M (1995) Cucurbitacins and their pharmacological effects. Phytother Res 9: 159-168.
30. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep 2005; 22: 386-399. Addtions and corrections Nat Prod Rep 2005; 22: 794-5.
31. Ríos JL, Escandell JM, Recio MC. In: Atta-Ur-Rahman, Ed. Studies in Natural Products Chemistry: Bioactive Natural Products, Vol. 32, Part L. Amsterdam: Elsevier Sci Publ 2005; pp. 429-469.
32. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-1279.
33. Shi X, Franko B, Frantz C, Amin HM, Lai R. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of tran-scription-3 signaling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol 2006; 135: 26-32.
34. Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z, Zhang J. JSI-124 inhibits glioblastoma multiforme cell proliferation through G2/M cell cycle arrest and apoptosis augment. Cancer Biol Ther 2008; 7: 1243-1249.
35. van Kester MS, Out-Luiting JJ, von dem Borne PA, Willemze R, Tensen CP, Vermeer MH. Cucurbitacin I inhibits STAT3 and induces apoptosis in Sézary cells. J Invest Dermatol 2008; 128: 1691-1695.
36. Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J. Syn-ergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunol Cell Biol 2008; 86: 506-514.
37. Lui VW, Yau DM, Wong EY, et al. Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 2009; 30: 2085-2094.
38. Banerjee S, Byrd JN, Gianino SM, et al. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res 2010; 70: 1356-1366.
39. Escandell JM, Kaler P, Recio MC, et al. Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: the role of p53 and p21. Biochem Pharmacol 2008; 76: 198-207.
40. Ishdorj G, Johnston JB, Gibson SB. Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells. BMC Cancer 2011; 11: 268-280.
41. + cells. Mol Cancer Ther 2010; 9: 2879-2892.
42. Hsu HS, Huang PI, Chang YL, et al. Cucurbitacin I inhibits tu-morigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 2011; 117: 2970-2985
43. Ishdorj G, Johnston JB, Gibson SB. Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Mol Cancer Ther 2010; 9: 3302-3314.
44. Gheeya JS, Chen QR, Benjamin CD, et al. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol Ther 2009; 8: 2386-2395.
45. Chan KT, Li K, Liu SL, Chu KH, Toh M, Xie WD. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 2010; 289: 46-52.
46. Thoennissen NH, Iwanski GB, Doan NB, et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69: 5876-5884.
47. Iwanski GB, Lee DH, En-Gal S, et al. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 2010; 160: 998-1007.
48. Lee DH, Thoennissen NH, Goff C, et al. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett 2011; 306: 161-170.
49. Liu T, Zhang M, Zhang H, Sun C, Deng Y. Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 2008; 265: 1225-1232.
50. Liu T, Zhang M, Zhang H, et al. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol 2008; 587: 78-84.
51. Liu T, Peng H, Zhang M, Deng Y, Wu Z. Cucurbitacin B, a small molecule inhibitor of the STAT3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cis-platin. Eur J Pharmacol 2010; 641: 15-22.
52. Chen W, Leiter A, Yin D, Meiring M, Louw VJ, Koeffler HP. Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines. Int J Oncol 2010; 37: 737-743.
53. Zhang M, Sun C, Shan X, Yang X, Li-Ling J, Deng Y. Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling. Pancreas 2010; 39: 923-929.
54. Haritunians T, Gueller S, Zhang L, et al. Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 2008; 32: 1366-1373.
55. Yin D, Wakimoto N, Xing H, et al. Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 2008; 123: 1364-1375.
56. Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H, Sakai T. Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol Nutr Food Res 2010; 54: 559-565.
57. Chan KT, Meng FY, Li Q, et al. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 2010; 294: 118-124.
58. Zhou X, Yang J, Wang Y, et al. Cucurbitacin B inhibits 12-O-tetradecanoylphorbol 13-acetate-induced invasion and migration of human hepatoma cells through inactivating mitogen-activated protein kinase and PI3K/Akt signal transduction pathways. Hepatol Res 2011; doi: 10.1111/j.1872-034X.2011.00933.x.
59. Yang L, Wu S, Zhang Q, Liu F, Wu P. 23,24-Dihydrocucurbitacin B induces G2/M cell-cycle arrest and mitochondria-dependent apoptosis in human breast cancer cells (Bcap37). Cancer Lett 2007; 256: 267-278.
60. Siqueira JM, Gazola AC, Farias MR, et al. Evaluation of the anti-tumoral effect of dihydrocucurbitacin-B in both in vitro and in vivo models. Cancer Chemother Pharmacol 2009; 64: 529-538.
61. Takahashi N, Yoshida Y, Sugiura T, Matsuno K, Fujino A, Yamashita U. Cucurbitacin D isolated from Trichosanthes kirilowii induces apoptosis in human hepatocellular carcinoma cells in vitro. Int Immunopharmacol 2009; 9: 508-513.
62. Ding N, Yamashita U, Matsuoka H, et al. Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-Cell leukemia. Cancer 2011; 117: 2735-2746.
63. Sun C, Zhang M, Shan X, et al. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol 2010; 136: 603-610.
64. Dong Y, Lu B, Zhang X, et al. Cucurbitacin E, a tetracyclic triter-penes compound from Chinese medicine, inhibits tumor angio-genesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 2010; 31: 2097-2104.
65. Li Y, Wang R, Ma E, et al. The induction of G2/M cell-cycle arrest and apoptosis by cucurbitacin E is associated with increased phosphorylation of eIF2a in leukemia cells. Anticancer Drugs 2010; 21: 389-400.
66. Shan XL, Zhou XY, Yang J, Wang YL, Deng YH, Zhang MX. Inhibitory effect of cucurbitacin E on the proliferation of ovarian cancer cells and its mechanism. Chin J Cancer 2010; 29: 20-24.
67. Boykin C, Zhang G, Chen YH, et al. Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation. Br J Cancer 2011; 104: 781-789.
68. Tannin-Spitz T, Grossman S, Dovrat S, Gottlieb HE, Bergman M. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol 2007; 73: 56-67.
69. van Dang G, Rode BM, Stuppner H. Quantitative electronic structure-activity relationship (QESAR) of natural cytotoxic compounds: maytansinoids, quassinoids and cucurbitacins. Eur J Pharm Sci 1994; 2: 331-350.
70. Escandell JM, Recio MC, Máñez S, Giner RM, Cerdá-Nicolás M, Ríos JL. Dihydrocucurbitacin B, isolated from Cayaponia tayuya, reduces damage in adjuvant-induced arthritis. Eur J Pharmacol 2006; 532: 145-154.
71. Escandell JM, Recio MC, Máñez S, et al. Dihydrocucurbitacin B inhibits delayed type hypersensitivity reactions by suppressing lymphocyte proliferation. J Pharmacol Exp Ther 2007; 322: 1261-1268.
72. Escandell JM, Recio MC, Máñez S, Giner RM, Cerdá-Nicolás M, Ríos JL. Cucurbitacin R reduces the inflammation and bone damage associated with adjuvant arthritis in Lewis rats by suppression of tumor necrosis factor-a in T lymphocytes and macrophages. J Pharmacol Exp Ther 2007; 320: 581-590.
73. Escandell JM, Recio MC, Giner RM, et al. Inhibition of delayed-type hypersensitivity by cucurbitacin R through the curbing of lymphocyte proliferation and cytokine expression by means of nuclear factor AT translocation to the nucleus. J Pharmacol Exp Ther 2010; 332: 352-363.
74. Sharma A, Sharma JP, Jindal R, Kaushik RM. Bottle gourd poisoning. JK Science 2006; 8: 120-121.
75. Recio MC, Prieto M, Bonucelli M, et al. Anti-inflammatory activity of two cucurbitacins isolated from Cayaponia tayuya roots. Planta Med 2004; 70: 414-420.
76. Molavi O, Ma Z, Mahmud A, et al. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors. Int J Pharm 2008; 347: 118-127.
77. Wang W, Zhao X, Hu H, et al. Galactosylated solid lipid nanopar-ticles with cucurbitacin B improves the liver targetability. Drug De-liv 2010; 17: 114-122.
78. Yang K, Wen Y, Li L, Wang C, Wang X. Acute toxicity and local stimulate test of cucurbitacinBE polylactic acid nano-particles of targeting cervical lymph nodes. Hua Xi Kou Qiang Yi Xue Za Zhi 2001; 19: 380-382. PMID: 12539689.
79. Yang K, Wen Y, Wang C. The study of cucurbitacin BE polylactic acid nanoparticles delivering cucurbitacin BE to metastasized cervical lymph nodes in mice with oral cancer. Hua Xi Kou Qiang Yi Xue Za Zhi 2003; 21: 477-480. PMID: 14732987.